SCHEMBL3554742

SCHEMBL3554742

C/C=C/c1ccc(NS(C)(=O)=O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.52
ALDH1A1 P00352 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
LMNA P02545 2/20 0.52
KDM4E B2RXH2 1/20 0.52
HPGD P15428 1/20 0.52
HTT P42858 1/20 0.52
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
KIF11 P52732 3/20 0.48
PGR P06401 1/20 0.46
NR3C2 P08235 2/20 0.44
MAPT P10636 1/20 0.44
CYP2C9 P11712 1/20 0.44
ESR1 P03372 1/20 0.44
GAA P10253 1/20 0.42
MAPK1 P28482 1/20 0.42
PTGS2 P35354 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15836266 1.00 KEAP1 (0.52) KEAP1ALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL14358816 0.90 KEAP1 (0.58) KEAP1ALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL14358814 0.90 KEAP1 (0.58) KEAP1ALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL5673137 0.83 KEAP1 (0.56) KEAP1ALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL27587461 0.82 CA12 (0.53) KEAP1ALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL15218448 0.82 KEAP1 (0.67) KEAP1ALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL12678665 0.81 HPGD (0.56) SMN1; SMN2LMNAHPGDHTTKIF11
SCHEMBL12054668 0.80 KEAP1 (0.75) KEAP1ALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL13508329 0.79 NR3C2 (0.49) KEAP1ALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL687551 0.79 CA1 (0.55) KEAP1ALDH1A1SMN1; SMN2LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2961741-B1 NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES FUND PARA LA INVESTIG MEDICA APLICADA (ES) 2017-04-05 EP disclosed
US-9573956-B2 Compounds as dual inhibitors of phosphodiesterases and histone deacetylases FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2017-02-21 US disclosed
US-20160002246-A1 NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2016-01-07 US disclosed
US-8975247-B2 Methods and compositions of treating a flaviviridae family viral infection THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNION UNIVERSITY (US) 2015-03-10 US disclosed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002246-A1 NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES PDE1A, HDAC1, HDAC2 KEAP1 829/4885ALDH1A1 316/4885SMN1; SMN2 975/4885
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B KEAP1 912/4885ALDH1A1 1136/4885SMN1; SMN2 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.